Skip to main content

Advertisement

Log in

ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis

European Radiology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Further reading

  1. Boome DR, Girguis M, Baron P, Cottrel A, Kjellin I, Kirk G (2007) Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Am J Roentgenol 188:586–592

    Article  Google Scholar 

  2. Center for Disease Control and Prevention (CDC) (2007) Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents-St. Louis, Missouri, 2002–2006. MMWR Morb Mortal Wkly Rep 56:137–41

    Google Scholar 

  3. Collidge TA, Thompson PC, Mark PB et al (2007) Gadolinium-enhanced magnetic resonance imaging and nephrogenic systemic fibrosis—a retrospective case-control study. Radiology (in press)

  4. Deo A, Fogel M, Cowper SE (2007) Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2:264–267

    Article  PubMed  Google Scholar 

  5. EMEA decision of 26.06.07. Available through http://www.esur.org. Assessed 10.08.07

  6. Grobner T (2006) Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104–1108

    Article  PubMed  CAS  Google Scholar 

  7. High W, Ayers RA, Chandler J, Zito G, Cowper SE (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:27–30

    Article  Google Scholar 

  8. Idée J-M, Port M, Raynal I, Schaefer, Le Greneur S, Corot C (2006) Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20:563–576

    Article  PubMed  CAS  Google Scholar 

  9. Khurana A, Runge VM, Narayanan M, Greene JF, Nickel AE (2007) Nephrogenic systemic fibrosis. A review of 6 cases romporally related to gadodiamide injection (Omniscan). Invest Radiol 42:139–145

    Article  PubMed  Google Scholar 

  10. Maloo M, Abt P, Kashyap R et al (2006) Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transpl 6:2212–2217

    Article  CAS  Google Scholar 

  11. Marckman P, Skov L, Rossen K et al (2006) Nephrogenic systemic fibrosis: suspected etiological role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359–2362

    Article  PubMed  Google Scholar 

  12. Morcos, SK (2007) Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast molecule an important factor in the pathogenesis of this condition? Brit J Radiol 80:73–76

    Article  PubMed  CAS  Google Scholar 

  13. Sadowski E, Bennett LK, Chan MR et al (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 43:148–157

    Google Scholar 

  14. Thomsen HS (2006) Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 16:2619–2621

    Article  PubMed  Google Scholar 

  15. Thomsen HS, Almén T, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (2002) Gadolinium-containing contrast media for radiographic examinations: a position paper. Eur Radiol 12:2600–2605

    PubMed  Google Scholar 

  16. Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR) (2005) In which patients should serum-creatinine be measured before contrast medium administration? Eur Radiol 15:749–754

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Henrik S. Thomsen.

Additional information

The content of this document presents the consensual opinion of only the Academic members of the ESUR Contrast Media Safety Committee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thomsen, H.S. ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol 17, 2692–2696 (2007). https://doi.org/10.1007/s00330-007-0744-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00330-007-0744-5

Navigation